Louis Fox, Research fellow at King’s College London, shared a post on LinkedIn:
“Yesterday at ESMO Congress was an important talk from the ever-eloquent Madeline Pe from EORTC’s Quality of Life Department about how fundamental methodological issues, such as timing of assessment and formulating suitable HRQoL research questions, are being persistently overlooked when it comes to assessing health-related quality of life outcomes in oncology trials (despite being a key ESMO criteria for assessing the merit of a treatment).
Today, I was able to join a highly engaging talks by Karin Jordan and Radu Vidra on the chronic and late-onset effects of immune checkpoint inhibitors, and the implications for health-related quality of life in the survivorship context for these patients (Spoiler alert: these effects are very high prevalence and likely to have significant ongoing HRQoL impact)
It’s good to see HRQoL being talked about a lot at ESMO and for me this only underscores how there is an unmet need for robust methods of HRQoL measurement in immuno-oncology that are reliable/valid.
So I’m glad to be presenting a poster at ESMO Congress on our work with the EORTC’s Quality of Life Group, on precisely this. We’ve used robust mixed methods, collecting data across ten countries and across cancer types, to produce a preliminary item list for the assessment of HRQoL specifically for patients receiving immune checkpoint inhibitors.
This item list is now available for use from the EORTC Quality of Life Group’s Item Library.
Check out our e-poster (ID: 3191eP) at ESMO Congress (in Hall 25) to find out more about the methods underlying this work.”
ESMO 2025 Day 3 Highlights Not to Miss.
